These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 31280296)

  • 1. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
    De Luca G; Cariddi A; Campochiaro C; Vanni D; Boffini N; Tomelleri A; Cavalli G; Dagna L
    Rheumatology (Oxford); 2020 Jan; 59(1):171-175. PubMed ID: 31280296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
    Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
    N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
    Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
    N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
    Hatemi G; Mahr A; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
    RMD Open; 2022 Jul; 8(2):. PubMed ID: 35798511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of apremilast for 3 months in Behçet's disease: A prospective observational study.
    Hirahara L; Kirino Y; Soejima Y; Takeno M; Takase-Minegishi K; Yoshimi R; Takeuchi M; Mizuki N; Nakajima H
    Mod Rheumatol; 2021 Jul; 31(4):856-861. PubMed ID: 32996801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Behçet's disease: A systematic review and meta-analysis.
    Iizuka Y; Takase-Minegishi K; Hirahara L; Kirino Y; Soejima Y; Namkoong HO; Horita N; Yoshimi R; Takeuchi M; Takeno M; Mizuki N; Nakajima H
    Mod Rheumatol; 2022 Oct; 32(6):1153-1162. PubMed ID: 34752620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast: A Review in Oral Ulcers of Behçet's Disease.
    Deeks ED
    Drugs; 2020 Feb; 80(2):181-188. PubMed ID: 31933168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.
    Hatemi G; Mahr A; Takeno M; Kim DY; Saadoun D; Direskeneli H; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
    Clin Exp Rheumatol; 2021; 39 Suppl 132(5):80-87. PubMed ID: 34622764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.
    Takeno M; Dobashi H; Tanaka Y; Kono H; Sugii S; Kishimoto M; Cheng S; McCue S; Paris M; Chen M; Ishigatsubo Y
    Mod Rheumatol; 2022 Feb; 32(2):413-421. PubMed ID: 34894266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease.
    Lopalco G; Venerito V; Leccese P; Emmi G; Cantarini L; Lascaro N; Di Scala G; Fabiani C; Rigante D; Iannone F
    Ann Rheum Dis; 2019 Dec; 78(12):1736-1737. PubMed ID: 31401548
    [No Abstract]   [Full Text] [Related]  

  • 11. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome.
    Özdede A; Hatemi G
    Expert Opin Pharmacother; 2021 Aug; 22(12):1533-1537. PubMed ID: 34218739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.
    Vieira M; Buffier S; Vautier M; Le Joncour A; Jamilloux Y; Gerfaud-Valentin M; Bouillet L; Lazaro E; Barete S; Misery L; Gobert D; Goulenok T; Fain O; Sacre K; Sève P; Cacoub P; Comarmond C; Saadoun D
    Front Immunol; 2020; 11():626792. PubMed ID: 33613571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positioning of apremilast in treatment of Behçet's disease.
    Takeno M
    Mod Rheumatol; 2020 Mar; 30(2):219-224. PubMed ID: 31747804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of apremilast and its impact on serum cytokine levels in patients with Behçet's disease.
    Wakiya R; Ushio Y; Ueeda K; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
    Dermatol Ther; 2022 Aug; 35(8):e15616. PubMed ID: 35668044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcome of Ustekinumab Therapy for Behçet's Disease.
    Mirouse A; Barete S; Desbois AC; Comarmond C; Sène D; Domont F; Bodaghi B; Ferfar Y; Cacoub P; Saadoun D;
    Arthritis Rheumatol; 2019 Oct; 71(10):1727-1732. PubMed ID: 31008548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Apremilast for Aphthous Ulcers in a Patient With Behçet’s Syndrome.
    Saini A; Ferguson C; Salkey K
    J Drugs Dermatol; 2018 Dec; 17(12):1328-1329. PubMed ID: 30586267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apremilast to treat oral ulcers in Behçet syndrome.
    Yazici H
    Drugs Today (Barc); 2020 May; 56(5):303-310. PubMed ID: 32406877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New mouthwash: an efficacious intervention for oral ulceration associated with Behçet's disease.
    Senusi A; Kang A; Buchanan JAG; Adesanya A; Aloraini G; Stanford M; Fortune F
    Br J Oral Maxillofac Surg; 2020 Oct; 58(8):1034-1039. PubMed ID: 32819746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab for Behçet's disease.
    Mirouse A; Barete S; Monfort JB; Resche-Rigon M; Bouyer AS; Comarmond C; Sène D; Domont F; Ferfar Y; Cacoub P; Saadoun D
    J Autoimmun; 2017 Aug; 82():41-46. PubMed ID: 28483439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation and reliability of a Behcet's Syndrome Activity Scale in Korea.
    Choi HJ; Seo MR; Ryu HJ; Baek HJ
    Korean J Intern Med; 2016 Jan; 31(1):170-5. PubMed ID: 26767871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.